ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced the sale of certain of its discovery and preclinical assets to Ardea Biosciences, Inc. (formerly IntraBiotics Pharmaceuticals). The sale includes the rights to Valeant s HIV and cancer development programs. Under the terms of the ag
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that it has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration ( FDA ) for the compan
STOCKHOLM, Sweden -- Tibotec Pharmaceuticals Inc, on behalf of the Medivir (STO:MVIRB) and Tibotec collaborative drug discovery project on hepatitis C virus (HCV), has filed an application with a European regulatory authority to commence the first phase I clinical trial of an HCV NS3/4A protease inhibitor. This trial i
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c47514) has announced the addition of Bristol-Myers Squibb Prospects to 2010 from Espicom Business Intelligence to their offering. Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the research and developme
STOCKHOLM, Sweden -- Medivir AB and Presidio Pharmaceuticals Inc announced today the signing of license agreements for alovudine (MIV-310), Medivir s phase II compound with potent activity against multidrug resistant HIV, and MIV-410 a preclinical compound which has a novel mechanism of action against HIV and is also e
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced preliminary results from the first cohort of a Phase 2b study of bevirimat (PA-457) in patients failing HIV therapy due to drug resistan
WASHINGTON -- Following the Libyan Criminal Court today confirming the death sentence on the Bulgarian and Palestinian medical personnel involved in the Benghazi case, European Commissioner for External Relations, Benita Ferrero-Waldner, issued the following statement: We simply can not accept this verdict and trust th
HOUSTON -- CytoGenix (OTCBB:CYGX) has demonstrated that a synDNA(TM) vaccine against human immunodeficiency virus (HIV) has activity in monkeys. The study, conducted by Drs. Yin Chen and Frederic Kendirgi at CytoGenix in collaboration with Lauren Hirao and Dr. David Weiner of the University of Pennsylvania, demonstrate
FOSTER CITY, Calif. & SILVER SPRING, Md. & ARLINGTON, Va. -- Gilead Sciences , Inc. (Nasdaq:GILD), the International Partnership for Microbicides (IPM) and CONRAD today announced an agreement under which Gilead has granted rights to IPM and CONRAD to develop, manufacture and, if proven efficacious, arrange for
WEST HAVEN, Conn. -- NanoViricides, Inc., (Pink Sheets: NNVC) Dr. Anil Diwan, Company President and Chairman, was selected to speak at Advances in Nanotechnology Conference - Biomedical Applications, 2006 held at the Moffitt Cancer Center in Tampa, FL, on Dec. 8th. He outlined the significant advantages of the nanoviri
WOBURN, Ma. & TOKYO -- VisEn Medical, Inc., a leader in fluorescence in vivo imaging from research through medicine, today announced that it has signed an exclusive distribution agreement with Olympus Corporation covering sales of the company s Fluorescence Molecular Tomography (FMT(TM)) imaging systems and portfol
MELBOURNE, Australia , & MENLO PARK, Calif. -- ChemGenex Pharmaceuticals (ASX: CXS, NASDAQ: CXSP) announced today the presentation of new phase 2 clinical data supporting the use of Ceflatonin(R) (homoharringtonine or HHT) in combination with imatinib mesylate (Gleevec(R)) to treat chronic myeloid leukemia (CML) pa
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the leader in oral fluid diagnostics, announced that its OraQuick ADVANCE(R) Rapid HIV 1/2 Antibody Test will be the centerpiece of a planned initiative in the City of Philadelphia to provide oral fluid rapid HIV 1/2 testing to populations that are traditional
NEW YORK -- (OTCBB:CEMI) Avi Pelossof, Chembio s Vice President of Sales, Marketing and Business Development, has resigned from Chembio to accept a new position that is being created at Inverness Medical Innovations, Inc. (AMEX:IMA) in which he will have global responsibility for all of Inverness HIV and other blood bo
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) announced today that it has been selected as the recipient of The AIDS Institute s 2007 Innovative HIV Life Science Leadership Award. The award was given based upon criteria which include: the pursuit of innovative approaches to controlling HIV, the demonstration of a co
DALLAS -- Today, on World AIDS Day Exxon Mobil Corporation honors efforts to combat the global HIV/AIDS epidemic. According to the latest figures from UNAIDS and the World Health Organization , an estimated 39.5 million people are living with HIV and there were 4.3 million new HIV infections in 2006. In 2006, 2.
OAK-BROOK,-Ill. -- According to a joint report issued by UNAIDS and WHO, an estimated 39.5 million people globally are living with HIV and an estimated 4.3 million individuals were newly infected during 2006. An overwhelming proportion of the people living with HIV are in Sub-Saharan Africa where the estimated number o
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c46367) has announced the addition of Antivirals - Global Strategic Business Report to their offering. This report analyzes the worldwide markets for Antivirals in US$ Million. The major product segments analyzed are HIV Antivirals (Reve
MEDFORD, N.Y. -- Chembio Diagnostics Inc. (OTCBB: CEMI) has received CLIA Waiver for one of its two FDA-approved rapid HIV tests, HIV 1/2 STAT-PAK(TM). The CLIA (Clinical Laboratory Improvement Act) waiver allows Chembio to market these HIV tests to a potential market of approximately 189,000 laboratory entities across
WATERTOWN, Mass. - Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that Panacos President and COO, Graham P. Allaway, Ph.D., made a plenary presentation on bevirimat (PA-457) at the 10th International Mee
STANFORD, Calif. -- The key to combating AIDS in Russia may be to treat HIV-infected drug users. A new model estimating the spread of HIV in Russia suggests that treating injection drug users with antiretroviral medication will slow transmission of the virus among the general population. The study, which will appea
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received a purchase order for 990,000 of its SURE CHECK(R) HIV 1/2 rapid tests from the Company s exclusive distributor in Mexico . The tests will be used for the Mexican Ministry of Health program to screen pregnant women. During the next several weeks, a shi
BOSTON -- New clinical data on the hepatitis C polymerase inhibitor R1626 - currently in development by Roche - show viral reductions greater than those described for other polymerase inhibitors, according to data presented at the 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).
DURHAM, N.C. -- Argos Therapeutics today announced that it has been awarded a $21 million National Institutes of Health contract to develop novel HIV immunotherapy candidates. Argos is developing personalized, RNA-loaded dendritic cell immunotherapy products designed to train the patient s immune system to recognize, t
SAN ANTONIO -- Southwest Research Institute has been awarded a four-year, $700,000 contract as a co-investigator under a U19 cooperative agreement grant through the National Institutes of Health to formulate siRNA microbiocides for targeted drug delivery to prevent HIV, as well as HSV and HPV. This program will look at
STANFORD, Calif. -- The U.S. Centers for Disease Control and Prevention recently announced new voluntary guidelines recommending that all Americans ages 13 to 64 be screened for HIV, the virus that causes AIDS. That s a significant change from the previous guidelines, which recommended testing only for high-risk indivi
RED MOTORAZR on High-Speed Power Vision Network Benefits (RED); Offers Exclusive Sprint Content and Live Television Channels - Customers Able to Help Fight HIV/AIDS in Africa Today by Reserving RED MOTORAZR at www.sprint.com/RED OVERLAND PARK, Kan. & LIBERTYVILLE, Ill.--(BUSINESS WIRE)--Oct. 13, 2006--Motorola (NYS
NUTLEY, N.J. -- Roche today announced the initiation of the first Phase II study to evaluate R1626, an investigational polymerase inhibitor, for the treatment of chronic hepatitis C. The drug has also been granted Fast Track designation by the U.S. Food and Drug Administration ( FDA ), a program designed to facilitate
MONTREAL & WHITEHOUSE STATION, N.J. -- Ambrilia Biopharma Inc., a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, and Merck & Co. , Inc., one of the world s leading pharmaceutical companies, announced today that Ambrilia has entered into an exclusive
NUTLEY, N.J. & MORRISVILLE, N.C. -- Roche and Trimeris, Inc. today provided an update on the companies development plans for administration of FUZEON(R) ( enfuvirtide ) with a needle-free injection device (Biojector(R) 2000, B2000). In recent discussions with FDA regarding the subm
BEIJING -- China Medical Technologies, Inc. (the Company ) (NASDAQ: CMED), a leading China-based medical device company that develops, manufactures and markets high intensity focused ultrasound products and advanced in-vitro diagnostic systems, today announced that it has successfully completed the development of two H
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that it will receive up to $3.56 million in new funding to support the development and manufacture of novel adenovector-based HIV vaccines under its multi-year collaboration with the Vaccine Research Center (VRC) of the National Institute of Allergy and In
NEW YORK -- Chembio Diagnostics, Inc. (OTCBB:CEMI) will host a conference call today, Tuesday October 10th at 4:30pm ET to discuss the recently announced financing and marketing partner agreements for Chembio s rapid HIV tests. Chembio invites all those interested in hearing management s discussion of the recent events
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43154) has announced the addition of Pipeline Insight: HIV - Extending Treatment Options to their offering. More people than ever are living with HIV and AIDS in North America and Western Europe. Over the next five years, a great variet
PRINCETON, N.J. & FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- -- Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences , Inc. (Nasdaq:GILD) and Merck & Co. , Inc. (NYSE:MRK) today announced the submission of a Marketing Authorisation Application (MAA) for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabin
NEW YORK -- Chembio Diagnostics, Inc. (OTCBB:CEMI) will host a conference call on Tuesday, October 10th at 4:30pm EST. The call will be held to discuss the marketing partner agreements, for their rapid HIV tests, and financing that was announced earlier today. A live web cast can be accessed by clicking on the followin
WALTHAM, Mass. & MEDFORD, N.Y. & FRAMINGHAM, Mass. -- Inverness Medical Innovations, Inc. (Amex: IMA), Chembio Diagnostics, Inc. (OTCBB:CEMI), and StatSure Diagnostic Systems, Inc. (OTCBB:SSUR) announced today that they had entered into a series of agreements that provide Inverness with exclusive worldwide mark
MEDFORD, N.Y. & FRAMINGHAM, Mass. -- StatSure Diagnostic Systems, Inc. (OTCBB:SSUR) and Chembio Diagnostics, Inc. (OTCBB:CEMI) announced today that they have entered into a series of agreements that provide Inverness Medical Innovations, Inc. (AMEX:IMA) with exclusive worldwide marketing rights to Chembio s FDA-cle
GAITHERSBURG, Md. -- GenVec, Inc. (Nasdaq:GNVC) announced today that it could receive up to $52 million under a new, five-year contract with the exercise of annual renewal options by NIAID, to support the transfer of its manufacturing and purification processes to the Dale and Betty Bumpers Vaccine Research Center s (V
NUTLEY, N.J. & MORRISVILLE, N.C. -- The following is a corrected version of a Business Wire release from October 5, 2006. The corrected release reads: NEW DATA SHOW UNPRECEDENTED UNDETECTABLE RATES OF OVER 90 PERCENT IN HIV PATIENTS RECEIVING FUZEON(R) AND INVESTIGATIONAL INTEGRASE INHIBITOR MK-0518 New data presen
SANTA FE, N.M. -- Dorothy H. Bray, Ph.D., will chair the Scientific Advisory Board at CytoDyn, Inc. (OTCBB:CYDY), the Company announced today. Dr. Bray has garnered extensive experience in the development of drugs for HIV/AIDS while serving in various senior positions at GlaxoSmithKline (NYSE:GSK) and its predecessors
CAMBRIDGE, Mass. -- The Pendulum Project, a non-profit humanitarian organization that helps families and communities care for, support, and protect orphans and vulnerable children in Malawi , a sub-Saharan African country that has been hard hit by AIDS, announced today that it has been granted official NGO status.
PRINCETON, N.J. & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc. (Nasdaq:GILD) today announced an agreement to commercialize ATRIPLA(TM) ( efavirenz 600 mg/ emtricitabine 200 mg/
SAN FRANCISCO -- Levels of total cholesterol and triglycerides were not increased in HIV-infected patients taking MK-0518, an investigational integrase inhibitor being developed by Merck & Co. , Inc., with tenofovir ( Viread (R)) and lamivudine (
SAN DIEGO -- On Call Employee Solutions, Inc., a privately-held staffing firm specializing in skilled administrative, accounting and finance, mortgage, and technical contractors, will join more than 12,000 participants in the 17th Annual AIDS Walk San Diego on Sunday, October 1, in Balboa Park. To help raise awareness
SAN FRANCISCO -- Gilead Sciences , Inc. (Nasdaq: GILD) today announced two presentations of long-term efficacy and safety data from Study 903E on the company s leading once-daily anti-HIV medication, Viread (R) ( tenofovir disoproxil fumarate).
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) disclosed today that it has published a paper entitled: A Clinical Report on the Safety of the Aethlon Hemopurifier(TM). The report details the landmark use of the Hemopurifier(TM) in a human infectious disease study conducted at the Apollo Hospital in Delhi,
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, announced today that it has commenced several laboratory-based operational studies as the initial stage of the process to obtain U.S. Food
NEW YORK -- Starpharma Holdings Ltd. (ASX:SPL) (OTC:SPHRY) has enrolled in the unique shareholder empowerment platform administered by Investrend Communications, Inc., a provider of financial intelligence programs. Benchmark research coverage will be initiated by analyst Mohammad Sharifzadeh, CFA, Ph.D., who is also le
NEW YORK -- Chembio Diagnostics, Inc. (OTCBB:CEMI) strongly supports the U.S. Centers for Disease Control and Prevention s (CDC) HIV testing final recommendations issued this morning that all Americans between the ages of 13 to 64 be tested for HIV as a part of routine medical care. Today s news comes just as the US Co
WATERTOWN, Ma. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced a presentation of the results of a clinical trial studying the interaction of bevirimat (PA-457), the Company s lead HIV drug candidate, a
SANTA FE, N.M. -- Prominent clinician and immunologist Robert H. Keller, M.D., M.C., FACP, AAHIVS has joined the Scientific Advisory Board of CytoDyn, Inc. (OTCBB:CYDY). Dr. Keller has been at the bedside of patients with HIV/AIDS since the beginning of the AIDS pandemic. His extensive experience in managing the diseas
SAN DIEGO -- Aethlon Medical, Inc., (OTCBB:AEMD) a pioneer in developing therapeutic devices for infectious disease, announced today that its President, Hal Handley, Ph.D. will present at The United States Conference on AIDS (USCA) this Friday, the 22nd of September. As a follow-up to Aethlon s presentation at the XVI
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR), an immuno-pharmaceutical company developing products to treat autoimmune and infectious diseases, announced today that James L. Foght, Ph.D., has joined the company s Board of Directors. Dr. Foght is Managing Partner of Foght Enterprises, L.L.C., which i
SEATTLE -- Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of a new patent that further strengthens the company s leadership in developing adeno-associated virus (AAV)-based therapies. U.S. Patent 7,105,345, titled Adeno-Associated Virus Serotype 1 Nucleic Acid Sequences, Vectors And Host Cells
NEW YORK -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received a new order for 396,000 HIV 1/2 STAT-PAK(TM) rapid tests. The Company plans to ship these tests, which will be used for voluntary counseling and testing programs in Nigeria , in September and October, 2006. The United States Presid
WEST HOLLYWOOD -- Since its inception the City of West Hollywood has been on the cutting edge of the fight against the HIV and AIDS epidemic. One special way the City preserves this tradition is through Team WeHo. Team WeHo is a group of employees from the City of West Hollywood who run national and international marat
LOS ANGELES--(BUSINESS WIRE)--Sept. 9, 2006--Academy Award-winning actor Denzel Washington has donated $1 million to Los Angeles-based Save Africa s Children to help in their efforts to provide direct support and raise awareness for an additional 300 orphan care projects across the continent. Currently, there are 17 mi
SAN DIEGO -- Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing therapeutic devices for infectious disease, announced today that its Hemopurifier(TM) is featured in a story entitled: Expanding HIV Therapy: Will Devices Pick Up Where Drugs Leave Off? The story was published in this week s issue of The Gray Shee
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company, presented results from an open-label 40-week extension study in painful HIV-associated neuropathy (HIV-AN) patients that indicated repeat treatment with Transacin(TM) (NGX-4010) resulted in consistent reductions in pain over the e
GAITHERSBURG, Md. -- GenVec, Inc. (NASDAQ: GNVC) announced today that results from multiple Phase 1 clinical trials were presented at the AIDS Vaccine 2006 Conference in Amsterdam this week. The HIV vaccine incorporating GenVec s adenovector-based technology was well tolerated, and results were consistent with previous
AMSTERDAM, Netherlands & SEATTLE -- Targeted Genetics Corporation (Nasdaq:TGEN) announced that Nathan Clumeck, M.D., Ph.D., Head of the Department of Infectious Diseases, St. Pierre University Hospital in Brussels, Belgium , will present interim results today from a Phase I clinical trial of tgAAC09, an investigati
SAN DIEGO -- Inovio Biomedical Corporation (AMEX:INO) announced today that its partner, Tripep AB of Sweden , has achieved additional positive pre-clinical results showing that its ChronVac-C DNA vaccine combined with Inovio s MedPulser(R) DNA delivery system produced a strong immune response against hepatitis C virus
GAITHERSBURG, Md. -- Study to Assess Effectiveness of a Vaccine Utilizing Boost Based on GenVec s Adenovector Technology and Proprietary Cell Line to Treat Patients Infected with Most Common Strains of HIV GenVec, Inc. (Nasdaq:GNVC) announced today that the first human therapeutic clinical trial involving the company s
MENLO PARK, Calif. -- Geron Corporation (Nasdaq:GERN) announced today the presentation of new data supporting the development of TAT0002, a small molecule telomerase activator for the treatment of HIV/AIDS, at the XVI International AIDS Conference in Toronto. The data, which were presented by Calvin Harley, Ph.D., Gero
TORONTO - New interim 24-week data from an ongoing Phase II dose-ranging study with MK-0518 twice daily (n=198), an investigational oral HIV integrase inhibitor under development by Merck & Co. , Inc., Whitehouse Station, N.J., U.S.A., in combination with tenofovir (
TORONTO - A worldwide expanded access program for HIV/AIDS patients with limited or no treatment options was announced today by Merck & Co. , Inc., Whitehouse Station, N.J., U.S.A., with respect to its investigational HIV integrase inhibitor, MK-0518, now in Phase III development. Program enrollment will begin in t
TORONTO - Reporting here at the 16th International AIDS Conference, Enzo Biochem, Inc. (NYSE:ENZ) described the results of long term follow-up studies of its StealthVector(R) HGTV43(TM) gene medicine as significant and perhaps unique. HIV-1 infected subjects treated with the proprietary retrovirus-based vector showed l
MEDFORD, N.Y. - Chembio Diagnostics, Inc. (OTCBB: CEMI) is featuring a new alternate procedure for performing its HIV 1/2 STAT-PAK Dipstick(TM) rapid test at this week s International AIDS Conference in Toronto, Canada . The International AIDS Conference is the world s largest conference for HIV/AIDS with an estimated
CARLSBAD, Calif. - The Immune Response Corporation (OTCBB:IMNR) announced today that it will restate its first quarter financial statements to add approximately $100 million of phantom income, which has nothing to do with the Company s operations. Also, there will be additional phantom income of similar magnitude in th
SAN DIEGO - Aethlon Medical, Inc. (OTCBB:AEMD) announced today that the Hemopurifier(TM), a medical device developed to treat drug and vaccine resistant pathogens, was presented as a candidate treatment for drug resistant HIV patients at The AIDS Institute s Treatment Horizons Forum held in conjunction with the XVI Int
NEW YORK - Plan USA, a world-wide non-profit organization dedicated to child-centered development and the well-being, rights and interests of children, today announced that renowned modern artist, Hilary Wallis, has volunteered to serve as Plan USA s Art Ambassador to Uganda . On her mission, Ms. Wallis is teaching chi
TORONTO, Ontario - Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the company has signed non-exclusive license agreements to provide generic versions of tenofovir disoproxil fumarate (sold by Gilead under the brand name Viread (R)) to th
TORONTO - Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the completion of preclinical studies indicating that their lead drug candidate, bevirimat (PA-457), is non-teratogenic, meaning it did not cause
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c40589) has announced the addition of The Top 50 Manufacturers of HIV/AIDS Diagnostic Tests & Systems to their offering. Five million people were infected across the world with HIV infection in 2005 taking the total beyond a record 4
TORONTO - Gilead Sciences , Inc. (Nasdaq:GILD) today announced the presentation of 96-week data from an ongoing clinical trial (Study 934) comparing a once-daily regimen of Viread (R) ( tenofovir disoproxil fumarate),
TORONTO - Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced it will present an update on its HIV fusion inhibitor program at the XVI International AIDS Conference in Toronto, Canada . A presentation de
NEW YORK - Beginning August 15, 2006, Macy s and LIFEbeat - the music industry s charitable organization dedicated to reaching America s youth with the message of HIV/AIDS prevention - are challenging high school and college students to a different kind of homework assignment: brainstorming creative ideas to raise awar
TORONTO - Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy (HAART), according to a study published in the August 15th issue of the Journal of Acquired Immune Deficiency Syndromes. These results will also be presented at the 2006 World AIDS Conference
TORONTO -- New interim 24-week data from an ongoing Phase II dose-ranging study with MK-0518 twice daily (n=198), an investigational oral HIV integrase inhibitor under development by Merck & Co. , Inc., Whitehouse Station, N.J., U.S.A., in combination with tenofovir (
FOSTER CITY, Calif. & WHITEHOUSE STATION, N.J. -- Gilead Sciences , Inc. (Nasdaq: GILD) and Merck & Co. , Inc. (NYSE: MRK) today announced that the companies have established an agreement for the distribution of ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/
AUSTIN, Texas -- SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guest is Joseph Cummins, President and CEO of Amarillo Biosciences (OTCBB:AMAR). The interview includes Mr. Cummins s personal insight into the company s recent news and more. The intervie
MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, today announced financial results for the second quarter and six months ended June 30, 2006.
SANTA FE, N.M.--(BUSINESS WIRE)--Aug. 4, 2006--CytoDyn, Inc. (OTCBB:CYDY) has been invited to present clinical results from Cytolin(R) at the Treatment Horizons Forum of The AIDS Institute to be held on August 12, 2006 in conjunction with the XVI International AIDS Conference in Toronto. CytoDyn will show how its targe
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received its first order from the new Supply Chain Management System (SCMS) established recently under the auspices of the U.S. President s Emergency Plan for AIDS Relief (PEPFAR). The order is for 50,000 HIV 1/2 STAT-PAK(TM) tests to be used in connection wit
MELVILLE, N.Y. -- Allion Healthcare, Inc. (NASDAQ: ALLI), a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, has moved the date it will announce financial results for the second quarter ended June 30, 2006, to after the close of U.S. financial markets on Tuesday, Aug
ORANGEVALE, Calif. -- BioMag Corp. (OTC: BMGC), through its wholly owned subsidiary Biospectrum Technologies Inc., announced today that it will attend the 16th International AIDS Convention Aug. 13-18, in Toronto. The conference theme, Time to Deliver, underscores the continued urgency in bringing effective HIV prevent
LA JOLLA, Calif. -- Local women s health company Instead Inc. and Tommy Thompson have formed a new company called Instead Sciences, Inc. to complete the final stage of clinical trials, product development and market launch of its promising microbicide Amphora(TM) (clinically known as Acidform). Amphora--which already h
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today the receipt of approvals to expand its Phase II IR103 study in drug-naive HIV patients to include clinical sites in France . The trial, which is currently ongoing at several sites in Italy , will examine IR103, a second-gene
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use (CHMP), a scientific committee of the European Medicines Evaluation Agency (EMEA), has confirmed that a marketing application for Transacin(TM) is eligible fo
NEW YORK -- Bioenvision, Inc. (NASDAQ:BIVN) Bioenvision today announced its abstract on Suvus(TM) has been accepted for the British Association for the Study of the Liver s 2006 Annual Meeting in Dublin. The meeting on September 7-8th at Trinity College provides Bioenvision the first opportunity to present data from a
LOS ANGELES -- CytRx Corporation (Nasdaq:CYTR) today announced completion of the Phase I clinical trial of the novel HIV DNA + protein vaccine that it has exclusively licensed. Analysis of the unblinded data confirmed previous preliminary conclusions that the HIV vaccine formulation DP6-001 was generally well tolerated
NEW ROCHELLE, N.Y. -- In recognition of the XVI International AIDS Conference taking place on August 13-18, 2006, in Toronto, and with the continuing urgency to disseminate authoritative information in AIDS research and clinical care, publisher Mary Ann Liebert, Inc. will provide free access to all archival online issu
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB: CEMI) has submitted a CLIA waiver application to the United States Food & Drug Administration for the Company s SURE CHECK(R) HIV 1/2 rapid diagnostic test. With this application, Chembio has submitted two rapid HIV tests applications for CLIA Waiver during the las
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB: CEMI) is featuring its Dual Path Platform (DPP(TM)) at this year s American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition, being held July 25 through July 27 at the McCormick Place Convention Center in Chicago. DPP is a new and in
ORANGEVALE, Calif. -- BioMag Corp. (OTC: BMGC) announced today that it has filed for a new patent for a revolutionary multi-assay diagnostic system designed specifically for blood banks, by turning what currently takes eight separate tests into one procedure. After extensive research and design, including in-depth pate
DEERFIELD, Ill. -- Dade Behring Inc. (NASDAQ:DADE), the world s largest company solely dedicated to clinical diagnostics, today announced that it has launched the Quadriga BeFree infectious disease testing system to the non-U.S. marketplace. The Quadriga BeFree System is a fully automated, high-throughput system used t
FOSTER CITY, Calif. - Gilead Sciences , Inc. (Nasdaq:GILD): Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the quarter ended June 30, 2006. Total revenues for the second quarter of 2006 were $685.3 million, up 38 percent compared to total revenues of $495.3 million for the second quar
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39650) has announced the addition of Pipeline Insight: Hepatitis C - Protease inhibitors to drive market expansion to their offering. An estimated 10 million people in the seven major markets have chronic HCV. The current standard of ca
HAYWARD, Calif. -- While traveling in Africa, President Bill Clinton announced that the Clinton Foundation HIV/AIDS Initiative (CHAI) has signed an agreement with Guava Technologies, a California-based company, that can reduce the cost of CD4 testing by up to 50%. CD4 cells are white blood cells that are critical to a
FOSTER CITY, Calif. & PRAGUE, Czech Republic -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced a donation to The Institute of Organic Chemistry and Biochemistry at the Academy of Sciences of the Czech Republic (IOCB) for the establishment of a Gilead Sciences Research Centre. Gilead will provide a $1.
PRINCETON, N.J. and FOSTER CITY, Calif. -- Product Developed Through U.S. Joint Venture between Bristol-Myers Squibb and Gilead Sciences , the First of Its Kind in HIV Treatment Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences, Inc. (Nasdaq:GILD) today announced the U.S. Food and Drug Administration (
MEDFORD, N.Y. -- Chembio Diagnostics Inc. (OTCBB: CEMI) has submitted a CLIA Waiver Application for the Chembio HIV 1/2 STAT-PAK(TM) rapid diagnostic test on July 7th, 2006. The CLIA waiver, if granted, will allow Chembio to market to approximately 189,000 laboratory entities across the United States , including doc
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39316) has announced the addition of Tuberculosis: Trends, Challenges, and Opportunities in a Resurging Market to their offering. TB is epidemic in many developing countries, owing in part to co-infection with HIV and the emergence and
LOS ANGELES -- Clearant, Inc. (OTCBB:CLRI) today announced that it received a groundswell of interest from orthopedic surgeons considering using sterile allograft implants in their practices during the recent American Orthopaedic Society for Sports Medicine (AOSSM) annual meeting in Hershey, Pennsylvania. More than 50
PRINCETON, N.J. -- Ricerca Biosciences Brings over 18 Years and 200 Pharmaceutical Companies Worth of Experience PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) (WKN:A0B79T) announced today that it has entered into a development agreement with Ricerca BioSciences, a world class pharmaceutical development lab. T
OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB:BGES) a developer of vaccines with broad preventative and therapeutic applications, is pleased to announce that the Company will be presenting at the 2006 C.E. Unterberg Towbin Emerging Growth Conference, July 11-12, at The Mandarin Oriental Hotel in New York. The pres
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38914) has announced the addition of The Pain Market Outlook to 2011 to their offering. The patient populations for neuropathic and nociceptive pain are large, and are driven by separate disease trends that necessitate pain relief; acro
SAN DIEGO -- Illumina, Inc. (NASDAQ:ILMN) announced today that it has introduced a new Sentrix(R) HumanHap Genotyping BeadChip that extends broad genomic coverage to all four populations studied by the International HapMap Project including the Yoruba in Ibadan, Nigeria . The Yoruba (see Note) show greater genetic dive
A national day of HIV awareness has led thousands to get tested to know their HIV/AIDS status. It s all part of a campaign to raise awareness of the disease and to promote good health in one s self and in others. Listen to this report at: http://media.medialink.com/WebNR.aspx?story=32157 SOURCE: Medialink and National
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) was recognized yesterday by The Honorable Tim Bishop, United States Congressman from the First District of New York, in a statement that was entered into the Congressional Record. In honor of National HIV Testing Day, Congressman Bishop praised Chembio s work in r
SEATTLE -- Targeted Genetics Corporation (Nasdaq:TGEN) announced today that it has entered into a collaboration and license agreement with the International Aids Vaccine Initiative (IAVI), Columbus Children s Research Institute (CCRI) at Columbus Children s Hospital and The Children s Hospital of Philadelphia (CHOP) in
SAN DIEGO -- While immigration issues are the topic of Congressional and Senate hearings, one issue that is more important and often overlooked is the state of health issues as they relate to both sides of the border. The International Community Foundation, a leader in border-health issues, today released a report - S
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced that it has entered into an approximate $6 million, multi-year purchase contract with the New York City Department of Mental Health and Hygiene to expand the use of OraQuick(R) ADVANCE(TM) Rapid HIV-
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today the development of a serum-free, chemically defined cell culture medium for the production of HIV-1 from HUT-78 cells, a human T-cell lymphoma cell line. A poster on the medium optimization process is being presented this week at the Vacci
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received an order from the procurement agent on behalf of the United States Centers for Disease Control office in Nigeria for 200,000 HIV 1/2 STAT-PAK(TM) rapid tests which are to be used for voluntary counseling and testing programs in that country.
TOULON, France -- Phase II Study Presented This Week at European HIV/AIDS Meeting in France The Immune Response Corporation (OTCBB:IMNR) announced today that preliminary Phase II study results of its second-generation HIV immunotherapy, IR103, demonstrated a positive safety profile and enhanced immunomodulatory effects
NUTLEY, N.J. & MORRISVILLE, N.C. -- A new analysis of the TORO studies presented in an oral session at the 15th International HIV Drug Resistance Workshop in Sitges, Spain demonstrate continued CD4 cell increases in some patients who continued with FUZEON(R) ( enfuvirtide
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the City of Washington, DC has agreed to purchase OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Tests for use in a city-wide HIV testing campaign being launched this week on June 27th, National HIV Testing Day. The campaign, led by Dr. Mar
OraSure Technologies, Inc. (NASDAQ: OSUR): WHAT: OraSure Technologies, Inc. (NASDAQ: OSUR) will take part in the official launch of the D.C. Health Department s city-wide HIV testing campaign on June 27, National HIV Testing Day (NHTD). The citywide campaign will encourage all District residents to learn their HIV stat
NUTLEY, N.J. & MORRISVILLE, N.C. -- The approval today of a ritonavir-boosted protease inhibitor (PI), darunavir, by the U.S. Food and Drug Administration ( FDA ) will enable physicians and patients to create a potent new treatment combination with FUZEON(R) ( enfuvirtide
Fear is a terrible affliction, whether it is the fear of treading on a land mine or the fear of not knowing if you are HIV positive. - Nelson Mandela, Johannesburg LONDON -- The Mineseeker Foundation has reached an agreement with Calypte, a US pharmaceutical company, to purchase a new AIDS test product called Aware(TM
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today the completion of the first stage of enrollment of drug-naive HIV patients in a Phase II clinical study being conducted in Italy . The study, which has enrolled a total of 31 returning patients from a previous trial and 54 new patients, wi
OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines with broad preventative and therapeutic applications, today announced that the Beijing Institute of Radiation Medicine has notified the Company that it has completed the planned pre-clinical safety and immunogenicity studies for Bio-Brid
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (NASDAQ:PANC) today announced that its President and CEO Samuel K. Skip Ackerman, M.D., 58, passed away yesterday evening at a New York hospital after suffering an apparent heart attack during a presentation at a conference yesterday afternoon. This tragic event comes a
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Trial Designed to Tackle HIV Drug Resistance (One or More of a Patient s Current HIV Drug Regime Stops Working Leading to a Lack of Treatment Options) -- Pre-clinical Studies Suggest SP01A Prevents HIV Virus Entry Into Healthy Cells -- Human Clinical Studies Su
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c38226) has announced the addition of HIV/AIDS Testing - Global Strategic Business Report to their offering. This report analyzes the worldwide markets for HIV/AIDS Testing in Thousands of Units. The Product segments analyzed include HIV
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today presented data demonstrating lack of rapid emergence of resistance to bevirimat in single and multiple dose monotherapy studies in HIV infected pa
WOBURN, Mass. -- Aphios Corporation today announced that it has been awarded United States Patent No. 7,037,534 B2 for chemiluminescence activated antiviral therapeutics. The development of new antiviral agents is an important and difficult task. In general, compared to other classes of anti-infectives, there is much l
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that it has completed enrollment in its 400-patient Phase 3 trial of its investigational drug Transacin(TM) (NGX-4010) in patients suffering from postherpetic neuralgia (PHN). Transacin is NeurogesX s novel high-co
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced the initiation of a Phase 2b clinical trial of bevirimat (previously designated PA-457), the Company s lead drug candidate for the treat
ORANGEVALE, Calif. -- June 7, 2006--BioMag Corporation (OTC:BMGC) announced today that it has entered into a memorandum of understanding with Bangkok RIA Group ( BRIA ), a laboratory, manufacturer and distributor of diagnostic services in Thailand . BRIA will make a formal application to the Health Ministry of Thailand
City of West Hollywood: -- City of West Hollywood Staff to Wear Black in Solidarity and Memory of Those Affected by the Disease WHAT: The City of West Hollywood, home to the largest concentration of people living with HIV/AIDS in Southern California, will commemorate the 25th anniversary of the first diagnosis o
NEW YORK -- Representatives from Lawyers Without Borders were invited to speak today at the 2006 UN High Level Meeting on AIDS about the failure of many countries to enforce the inheritance rights of children who have lost parents to the disease. Volunteers from Shearman & Sterling, McDermott Will & Emery, Whit
NEW YORK -- Eighty-Four Percent of Companies Surveyed in Global Business Coalition on HIV/AIDS (GBC) and Booz Allen Hamilton New Study Ensure That Their Workers Have Access to HIV/AIDS Treatment Today, during opening day of the UN High Level Meetings on AIDS, GBC President and CEO Ambassador Richard Holbrooke,
OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB: BGES), a developer of vaccines with broad preventative and therapeutic applications, today announced that it has completed the major construction of a new state-of-the-art GMP research and manufacturing facility located in Beijing. The facility will provide a high qua
NORTH CHELMSFORD, Mass. -- SuturTek Incorporated, a medical device company with a unique, patented, award-winning suturing solution, today announced that it is bringing suture needle stick prevention to the operating room. Used by hundreds of surgeons in hospitals across the U.S., the 360-degree Fascia Closure Device(T
MEDFORD, N.Y. -- Lawrence Siebert, President and CEO of Chembio Diagnostics, Inc. (OTCBB:CEMI), was selected as a private sector delegate to the United Nation s High Level Meetings on AIDS to be held on May 31st - June 2nd, 2006 in New York. This is the first time that the private sector has been incorporated into the
PRINCETON, N.J. -- PhytoMedical Technologies, Inc. (OTCBB:PYTO) (FWB:ET6) today announced that Dr. Bruce D. Cherksey has exercised his option to acquire a 12-1/2 percent equity stake in the Company s wholly-owned subsidiary, PhytoMedical Technologies Corporation, pursuant to an exclusive, worldwide licensing agreement.
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- Data Shows 0.4 log10 Difference Between the High-Dose and the Placebo Control Group -- Dose dependent relationship in the number of subjects who had a reduction in viral load with the high dose group showing the most difference as compared to placebo (55% SP-01
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received approval from the U.S. Food and Drug Administration ( FDA ) for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid test Pre-Market Applications (PMAs). The approved PMAs allow Chembio to market its rapid HIV tests to clinical laboratories and ho
STANFORD, Calif. -- Three years ago Mark Kay, MD, PhD, published the first results showing that a hot new biological phenomenon called RNA interference was an effective gene-therapy technique in mice. That finding kicked off an RNAi gene therapy research flurry amongst both academic and industry research groups. Now, w
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics, today announced the appointment of Jack Goldstein, Ph.D. as a member of the Company s Board of Directors. Dr. Goldstein will serve as a Class I Director with an initial term expiring at the Company s 2007 Annual Mee
SCOTTSDALE, Ariz. -- Health Enhancement Products Inc., (OTCBB:HEPI) announced today that the HIV clinical trials for HEPI s ProAlgaZyme product, recently approved to be conducted in Cameroon , commenced on Friday, May 19, 2006. The trial will explore ProAlgaZyme s (PAZ) potential to reduce viral loads in patients with
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ: OSUR), the market leader in oral fluid diagnostics, announced today that The Centers for Disease Control and Prevention ( CDC ) has provided the Company with a purchase order for the immediate bulk procurement of its OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Te
STANFORD, Calif. -- The most striking image of Ethiopia for Kevin Montgomery was a corridor in the Black Lion Hospital in Addis Ababa crammed with more than 1,000 AIDS patients. Gurneys with patients lined the hallway. Crowds of patients milled about, leaning against walls, waiting for hours, sometimes for days. Outsid
CARLSBAD, Calif. -- Latest Progress on Company s Immune-based Therapy Programs for Multiple Sclerosis (MS) and Human Immunodeficiency Virus (HIV) will be Discussed The Immune Response Corporation (OTCBB:IMNR) announced it will present an overview of the Company s immune-based therapies, now in Phase II clinical trials
BASKING RIDGE, N.J.--Millennium Biotechnologies, Inc. -- SOD/gliadin Study Involving AIDS patients to be viewed by Over 20,000 Health Professionals from more than 150 Countries at the XVI International AIDS Society (IAS) Conference, the Worlds Largest Conference on HIV/AIDS, in Toronto Canada 2006 Millennium B
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) supports the U.S. Centers for Disease Control and Prevention (CDC) plans to issue revised HIV testing guidelines which recommend that doctors begin voluntary HIV testing as a part of routine medical care, for everyone in the United States between the ages of 1
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced that it has issued notice to terminate its Standby Equity Distribution Agreement (SEDA), equity line of credit arrangement, with Cornell Capital Partners, LP. The termination of the SEDA is an important milestone in our long-term financing strat
WOBURN, Mass. -- Aphios Corporation today announced that it has been awarded United States Patent No. 7,033,813 for vaccines for AIDS, influenza and other infectious diseases. Vaccination is the most cost effective tool for the control and prevention of infectious diseases. This could be true for HIV/AIDS that is runni
SAN DIEGO -- Throughout Africa, people living with HIV are becoming ill and dying prematurely because of avoidable health problems made worse by poor nutrition and inadequate access to food. San Diego-based Project Concern International and partners are responding to the urgent need to address HIV/AIDS and hunger as du
SAN DIEGO - Throughout Africa, people living with HIV are becoming ill and dying prematurely because of avoidable health problems made worse by poor nutrition and inadequate access to food. San Diego-based Project Concern International and partners are responding to the urgent need to address HIV/AIDS and hunger as dua
LAS VEGAS -- Samaritan Pharmaceuticals (AMEX:LIV): -- Completed Phase II Stage 1 (10 Day Monotherapy) -- Expect to Report Stage I Preliminary Results at Shareholders Meeting May 31st -- Expect Final PII Stage I Report July -- Currently Enrolling Phase II Stage 2 Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of
SCOTTSDALE, Ariz. -- Health Enhancement Products Inc. (OTCBB: HEPI) announced today that it will commence two separate clinical trials, one of which will study the possible effects of HEPI s sole product, ProAlgaZyme (PAZ) on HIV. In particular, the study will explore PAZ s potential to reduce viral loads in patients w
CARY, N.C. -- A veteran team of five former Glaxo executives has joined Trana Discovery, Inc. (formerly known as Neos Discovery) to commercialize technology that identifies drug compounds that interrupt the lifecycle of pathogens through a novel mechanism of action - the inhibition of transfer ribonucleic acid (tRNA).
LUSAKA, Zambia & SEATTLE -- The Zambia Emory HIV Research Project (ZEHRP), the International AIDS Vaccine Initiative (IAVI) and Targeted Genetics Corporation (Nasdaq: TGEN) today announced the initiation of a clinical trial in Zambia to test the safety and immunogenicity of tgAAC09, a preventive HIV vaccine. Th
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today that it has posted a presentation to its website that reviews the Company s new and expanded corporate strategy. The presentation was given by Immune Response President and CEO, Dr. Joseph O Neill, yesterday in New York to investors that p
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received an approvable letter from the U.S. Food and Drug Administration ( FDA ) for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid test Pre-Market Applications (PMAs). The rapid HIV tests detect HIV-1 and HIV-2 antibodies in four different sample ma
BOYNTON BEACH, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis, has announced that Designer Diagnostics, a wholly owned subsidiary of Nutra Pharma, and Svizera Labs have agreed in principal to supply Designer Diagnostics Test Kits to the
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): -- PII/III HIV Oral Entry Inhibitor Drug -- Cardiovascular Drug SP-1000 -- Alzheimer s Drug SP-233 -- Alzheimer s Blood Diagnostic -- Breast Cancer Diagnostic -- Alzheimer s Animal Model Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, an
BOSTON -- Proteome Systems (ASX:PXL) today announced that its international partner, the Foundation for Innovative New Diagnostics (FIND), has signed off on the second Milestone in its Tuberculosis (TB) diagnostic program, saying it is on track for the development of a rapid point-of-care (POC) test to control the spre
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. s (OTCBB:CEMI) HIV 1/2 STAT-PAK(TM) and HIV 1/2 STAT-PAK(TM) Dipstick tests have been evaluated and recommended for use in Kenya . Both tests were evaluated by the National AIDS/STD Control Programme of the Kenyan Ministry of Health and met their sensitivity and specificity re
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present at the BioCentury Future Leaders Conference to be held at Millennium Broadway Hotel & Conference Center in New York, NY on March 30, 20
GALLOWAY TOWNSHIP, N.J. -- The D Arcy Law Firm, P.C., today announced that it has joined forces with Motley Rice LLC, of Mt. Pleasant, S.C., and Cohen Placitella & Roth of Red Bank, N.J., to file suit in connection with allegedly illegally harvested and unscreened body parts used in transplant surgery. Together, th
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c34709) has announced the addition of the Decision Resources report Emerging Antiviral Drug Targets to their offering In recent years, many pharmaceutical and biotechnology companies have shifted their drug development for infectious dis
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI), has made substantial progress towards the launch of its PrimaTB STAT-PAK(TM) rapid test and pending completion of the external reproducibility studies and USDA facility inspection and licensure, plans commercial release of the test in late 2006. The test is for s
PORTSMOUTH, England -- Patients undergoing procedures that suppress their immune systems, such as bone marrow transplant or chemotherapy, face many risks when they leave the hospital. Highly vulnerable to infection, these patients return to their homes where the simple act of taking a shower may expose them to dangerou
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, today issued a statement following a meeting of the Blood Products Advisory Committee ( BPAC ) of the Food and Drug Administration (
MEDFORD, N.Y. -- Chembio is pleased by the recommendation that was given to the Food & Drug Administration ( FDA ) by FDA s Blood Products Advisory Committee (BPAC) on Friday, March 10 concerning proposed regulatory requirements for the approval of over the counter (OTC) distribution of rapid HIV tests. The BPA
OAK BROOK, Ill. -- Bio-Bridge-Science Inc. (OTCBB:BGES) announced that CEO Dr. Liang Qiao is featured in an interview with CEOcast. The topics of discussion include the company s unique technology platform and its promising new HIV vaccine. Dr. Qiao also elaborates upon Bio-Bridge Science s plans and prospects for the
NEW YORK -- Worldwide Orphans Foundation (WWO) has received a grant of $80,000 from Keep A Child Alive (KACA). The money is earmarked for WWO s medical programs that provide antiretroviral (ARV) therapy to Ethiopian children who are HIV positive. The mission of Worldwide Orphans Foundation is to identify the immediate
-- OraSure Technologies, Inc. (NASDAQ:OSUR): WHAT: OraSure Technologies, Inc. (NASDAQ:OSUR) CEO and President Douglas Michels will host an on-site media briefing following the Blood Products Advisory Committee (BPAC) meeting on March 10, 2006, to address the outcomes and next steps resulting from the BPAC discussion, a
SANTA FE, N.M. --Allen D. Allen, Chairman and CEO of CytoDyn, Inc. (OTCBB:CYDY), has acquired the rights to a cancer fighting compound from Dr. Vera Stecher, his longtime friend and colleague, who discovered the compound during a scientific expedition. At the time, Dr. Stecher was working for Roche (Pink Sheets:RHHBF).
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today, it is starting a second Phase II monotherapy trial, of its lead oral entry inhibitor anti-viral agent SP01A, in treatment experienced HIV-infected patients. Dr. Thomas Lang, Samaritan s Chief Drug Development Office
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration ( FDA ) has granted traditional approval status to its once-daily antiretroviral Viread (R) ( tenofovi
WHITEHOUSE STATION, N.J. -- On the fifth anniversary of the announcement of its worldwide HIV/AIDS pricing policy, Merck & Co. , Inc.(1) today further reduced the price of its HIV/AIDS medicine, STOCRIN ( efavirenz ), in the least developed countries of the world and those hardest hit by the epidemic.
CHICAGO -- Sharon Harkavy, Publisher of Hotshotstocks.com, today announced profile coverage of Aethlon Medical,Inc. (OTC BB:AEMD). Aethlon Medical is a publicly traded company based in San Diego, California. Since June of 2001, the sole focus of the company has been the development of a broad spectrum viral and toxin t
FARMINGDALE, N.Y. -- Enzo Biochem, Inc. (NYSE:ENZ) announced today that Enzo Therapeutics, its wholly owned subsidiary has received approval from the Committee on Human Research (CHR) at the University of California San Francisco (UCSF) to continue the clinical evaluation of the Company s Stealth Vector(R) HGTV43(TM) g
SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has been advised by its investigators in the United States and Hong Kong that there is no derogatory information that would preclude the Company from joining with Timeway International for a joint venture in China .
MEDFORD, N.Y. -- The Nigerian Ministry of Health announced this week that Chembio Diagnostics, Inc. s (OTCBB:CEMI) HIV 1/2 STAT-PAK(TM) is designated as a screening test in four out of the eight testing protocols that comprise Nigeria s Interim National Testing Algorithm. Nigeria is initially implementing a parallel te
SANTA FE, N.M. -- The law presumes that a company s management and affiliates, i.e., the insiders, always know more about the company than the man-on-the-street. This is not always the case in a global economy. A publicly traded company can have shareholders who know more about the marketplace than can be known to the
CONCORD, Calif. -- Cerus Corporation (Nasdaq:CERS) announced today the formation of a Blood Safety Scientific Advisory Board (SAB) to support with the company s initiatives in commercializing the INTERCEPT Blood System. The eight-member board, comprised of recognized leaders in the fields of transfusion medicine, blood
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB: CEMI) has appointed Setema, Ltd. to distribute its rapid HIV tests in Ethiopia . Ethiopia has a population of over 73 million of which an estimated 1.5 million are infected with HIV. Under the auspices of the President s $15 billion Emergency Plan for AIDS Relief (PEPF
TARRYTOWN, N.Y. -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that PRO 140 has been designated a fast track product by the U.S. Food and Drug Administration ( FDA ) for the treatment of human immunodeficiency virus (HIV) infection. The FDA Fast Track Development Program facilitates development and e
LOS ANGELES -- Shareholders attending the 2005 Annual Meeting of CytoDyn, Inc. (OTCBB:CYDY) in Los Angeles, Calif., were treated to a multimedia scientific presentation by Dr. Glenn Morrison, Director of Clinical Development for Symbion Research International, CytoDyn s CRO. The report by Dr. Morrison detailed the huma
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today that the final results from a Phase II clinical study indicate that the Company s whole-inactivated HIV-1 immunogen induces HIV-specific immune responses in HIV-infected, antiretroviral drug-naive patients. Specifically, this original form
SEATTLE -- Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes. U.S. patent #6,995,006 is titled, Methods for generating high titer helper-free preparation of released recombinant AAV vectors. The pat
DENVER -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced results of a Phase I/II dose-escalation study of GS 9137, or JTK-303, a novel oral HIV integrase inhibitor. The data, presented this week at the 13th Conference on Retroviruses and Opportunistic Infections (CROI) by Edwin DeJesus, MD, FACP, Medical Director
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq:PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, today announced that its lead product candidate, the HIV maturation inhibitor PA-457, was the subject of three presentations at the 13th Conference on R
DENVER -- Merck & Co. , Inc.: -- MK-0518, in Combination with Optimized Background Therapy (OBT), Provided Greater Viral Suppression vs. Placebo Plus OBT After 16 Weeks of Therapy in HIV Patients Infected with Highly Resistant Virus and Failing Multiple Therapies -- After 16 Weeks of Therapy, MK-0518 plus OBT was G
SAN CARLOS, Calif. -- NeurogesX, Inc., a privately held specialty pharmaceutical company, today announced that a webcast presentation of positive Phase 3 trial results in painful HIV-associated sensory neuropathy (HIV-AN) is available on the company s Web site at www.neurogesx.com . David Simpson, M.D., Professor of Ne
OAK BROOK, Illinois -- Bio-Bridge Science Inc. (OTCBB:BGES), a development-stage biotech company, announced today that its encouraging results for pharmacological and acute toxicity studies on its HIV therapeutic Vaccine (HIV-PV pseudovirus) on mice and monkeys will be a feature in the Corporate News section of Investo
CARLSBAD, Calif. -- The Immune Response Corporation (OTCBB:IMNR) announced today that its management and the Board of Directors are implementing a new corporate and clinical strategy designed to position the Company for long-term success by more effectively leveraging its core immune-based technology for autoimmune and
NASHVILLE, Tenn. & PROVO, Utah & DENVER -- Vanderbilt University, Brigham Young University and Ceragenix Pharmaceuticals, Inc. today announced that one of a family of compounds, called Ceragenins (or CSAs) shows potent virucidal activity in in vitro laboratory tests against multiple strains of Human Immunodefic
LOS ANGELES -- The Los Angeles County Office of AIDS Programs and Policy (OAPP) wants to raise awareness of the HIV/AIDS epidemic in the African American community and promote education and testing for those at risk for the infection and treatment for those with known HIV infection. National Black HIV/AIDS Awareness Da
BETHLEHEM, Pa. -- OraSure Technologies, Inc. (NASDAQ:OSUR), the market leader in oral fluid diagnostics and the manufacturer of the OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Antibody Test, today issued a statement in support of the Administration s recently-announced initiative to increase efforts to prevent, treat and ult
MEDFORD, N.Y. -- Chembio Diagnostics Inc. (OTCBB:CEMI) reported that during the last five weeks it has shipped approximately $540,000 of the Company s rapid HIV tests to the Ministry of Health of the Republic of Uganda . As previously announced by the Ugandan Ministry of Health, Chembio s HIV 1/2 STAT-PAK(TM) test is d
OAK BROOK, Ill. -- Bio-Bridge Science Inc. (OTCBB:BGES), a development-stage biotech company, reported encouraging results for pharmacological and acute toxicity studies on its HIV therapeutic Vaccine (HIV-PV pseudovirus) on mice and monkeys. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an
LOS ANGELES -- Hythiam, Inc. (NASDAQ:HYTM), a healthcare services management company that licenses the PROMETA(TM) physiological protocols designed to treat alcohol, methamphetamine and cocaine dependence, announced today that the PROMETA protocols have been licensed to Beverly Hills physician Gary Ross Cohan, M.D., F.
BOYNTON BEACH, Fla. -- Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced that it has signed a definitive agreement with NanoLogix, Inc. (Pink Sheets:NNLX) that will allow Nutra Pharma to ma
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has appointed Anudha, Ltd. to distribute the company s rapid HIV tests in Tanzania . Anudha Ltd. is a well known distributor in Tanzania that works closely with the Tanzanian government. Chembio, whose HIV STAT-PAK(TM) Dipstick is part of the national testing prot
MEDFORD, N.Y. -- Chembio Diagnostics, Inc. (OTCBB:CEMI) has received a $1.2 million purchase order for its Chagas STAT-PAK(TM) rapid test. The purchase order is from a leading Pan-American public health organization and is to supply the National Chagas Program that has been established by Bolivia s Ministry of Health.
FOSTER CITY, Calif. -- Publication Describes Superior Viral Suppression with Fewer Adverse Events Leading to Discontinuation for Patients Taking Viread and Emtriva at 48 Weeks Gilead Sciences , Inc. (Nasdaq:GILD) today announced the publicatio
SANTA FE, N.M. -- CytoDyn, Inc. (OTCBB:CYDY) has firmed up the date for its Annual Meeting to be held at 11:00 AM Pacific Time on January 31, 2006 in Studio City (Los Angeles), California. Shareholders attending will hear a scientific presentation on the status of the development track for Cytolin(R), the first targete
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today, the new FDA guidelines for early phases of drug development are expected to make it easier for Samaritan to manufacture small quantities of compounds for Phase I trials. The FDA s new guidance is intended to stream
FOSTER CITY, Calif. -- Gilead Sciences , Inc. (Nasdaq:GILD) today announced that it has completed a Phase I/II study of JTK-303, or GS 9137, an oral HIV integrase inhibitor for the treatment of HIV licensed from Japan Tobacco (JT) in March 2005. The company anticipates presenting results from the Phase I/II dose-escala
-- Companies Anticipate Filing New Drug Application in Second Quarter of 2006 NEW YORK & FOSTER CITY, Calif. -- Bristol-Myers Squibb Company (NYSE:BMY) and Gilead Sciences , Inc.(Nasdaq:GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of Bris
WATERTOWN, Mass. -- Panacos Pharmaceuticals, Inc. (Nasdaq: PANC), a biotechnology company dedicated to developing the next generation of antiviral therapeutic products, will present and provide a clinical update at the JP Morgan 24th Annual Healthcare Conference to be held at the Westin St. Francis hotel in San Francis
LAS VEGAS -- Samaritan Pharmaceuticals Inc. (AMEX:LIV): Decision to Advance SP-01A Starts Off With: -- Extensive Preclinicals -- A PIb/IIa 29-Patient ARA Study -- And Concluding PIIb 10-Day Monotherapy Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, announced today it is conducting a second
This information is designed to support, not replace, the relationship that exists between you and your doctor.